278 related articles for article (PubMed ID: 15449974)
1. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
Dranitsaris G; Kahn SR; Stumpo C; Paton TW; Martineau J; Smith R; Ginsberg JS;
Am J Cardiovasc Drugs; 2004; 4(5):325-33. PubMed ID: 15449974
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.
Sullivan SD; Davidson BL; Kahn SR; Muntz JE; Oster G; Raskob G
Pharmacoeconomics; 2004; 22(9):605-20. PubMed ID: 15209529
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
Sullivan SD; Kwong L; Nutescu E
Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
[TBL] [Abstract][Full Text] [Related]
5. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
6. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.
Bjorvatn A; Kristiansen F
Am J Cardiovasc Drugs; 2005; 5(2):121-30. PubMed ID: 15725043
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
Spruill WJ; Wade WE; Leslie RB
Blood Coagul Fibrinolysis; 2004 Oct; 15(7):539-43. PubMed ID: 15389119
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
11. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
Ross Terres JA; Lozano-Ortega G; Kendall R; Sculpher MJ
BMC Cardiovasc Disord; 2015 Dec; 15():180. PubMed ID: 26715178
[TBL] [Abstract][Full Text] [Related]
14. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
Tran AH; Lee G
Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in hip fracture surgery.
Wade WE; Spruill WJ; Leslie RB
Am J Ther; 2004; 11(3):194-8. PubMed ID: 15133534
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
[TBL] [Abstract][Full Text] [Related]
17. Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.
Farias-Eisner R; Horblyuk R; Franklin M; Lunacsek OE; Happe LE
Curr Med Res Opin; 2009 May; 25(5):1081-7. PubMed ID: 19298219
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
[TBL] [Abstract][Full Text] [Related]
19. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
Reynolds NA; Perry CM; Scott LJ
Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]